Co-Authors
This is a "connection" page, showing publications co-authored by Yaseen Arabi and Srinivas Murthy.
Connection Strength
1.197
-
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med. 2021 Aug; 47(8):867-886.
Score: 0.239
-
Correction to: COVID-19: a novel coronavirus and a novel challenge for critical care. Intensive Care Med. 2020 05; 46(5):1087-1088.
Score: 0.220
-
COVID-19: a novel coronavirus and a novel challenge for critical care. Intensive Care Med. 2020 05; 46(5):833-836.
Score: 0.217
-
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26; 385(9):790-802.
Score: 0.060
-
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26; 385(9):777-789.
Score: 0.060
-
Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021 May 14; 12(1):3001.
Score: 0.059
-
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021 04 15; 12(1):2349.
Score: 0.059
-
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021 04 22; 384(16):1491-1502.
Score: 0.058
-
CMAJ. 2020 10 26; 192(43):E1323-E1333.
Score: 0.057
-
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020 10 06; 324(13):1317-1329.
Score: 0.057
-
The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design. Ann Am Thorac Soc. 2020 07; 17(7):879-891.
Score: 0.056
-
Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline. CMAJ. 2020 05 19; 192(20):E536-E545.
Score: 0.055